Scientific publications

List of Dr. Gyula Kulcsár’s scientific publications

Releases:

11. Tamás Czömpöly, Zoltán Langmár, Mária Bors, Csilla Zsákai, Mária Géczy, Gyula Kulcsár (2014) Safety, Tolerability, and Effect on Quality of Life of a Mixture of Amino Acids and Other Small Molecules in Cancer Patients. Cancer Biotherapy & Radiopharmaceuticals, Volume 29, Number 3, 124-134 >>DOWNLOAD>>

10. Gyula Kulcsár, Dezső Gaál, Péter I. Kulcsár, Ákos Schulcz, Tamás Czömpöly (2013) A mixture of amino acids and other small molecules present in the serum suppresses the growth of murine and human tumors in vivo. International Journal of Cancer, 132: 1213-1221 >>DOWNLOAD >>

9. Kulcsár Gy. (2009) Experimental Evidence for Killing the Resistant Cells and Raising the Efficacy and Decreasing the Toxicity of Cytostatics and Irradiation by Mixtures of the Agents of the Passive Antitumor Defense System in the Case of Various Tumor and Normal Cell Lines in Vitro. Cancer Biotherapy & Radiopharmaceuticals, 24: 67-80. >>DOWNLOAD >>

8. Kulcsár Gy. (2005) Short review of the scientific basis of antitumor effect of Culevit food supplement. Rossijskij Bioterapevticeskij Journal, 4: 84-91.

7. Kulcsár Gy. (2003) Experimental evidence for the existence of the passive antitumor defense system formed by the synergistic action of certain small substances of the circulatory system. Cancer Biotherapy & Radiopharmaceuticals, 18: 949–962. >>DOWNLOAD>>

6. Kulcsár Gy. (2000) Synergistic potentiating effect of d(+) mannose, orotic and hippuric acid on selective toxicity of mixture of thirteen substances of the circulatory system for various tumour cell lines in culture. Cancer Detection and Prevention, 24: 485–495. >>DOWNLOAD>>

5. Kulcsár Gy. (1997) Theoretical and literary evidence for the existence of the passive antitumor defense system. Cancer Biotherapy & Radiopharmaceuticals, 12: 281–286. >>DOWNLOAD>>

4. Kulcsár Gy. (1997) Apoptosis of tumor cells induced by substances of the circulatory system. Cancer Biotherapy & Radiopharmaceuticals, 12: 19–26. >>DOWNLOAD>>

3. Kulcsár Gy. (1995) Inhibition of the growth of a murine and various human tumor cell lines in culture and in mice by mixture of certain substances of the circulatory system. Cancer Biotherapy, 10: 157–176. >>DOWNLOAD>>

2. Hankovszky H. O., Hideg K., Lex L., Kulcsár Gy. and Halász H. A. (1982) Methods for preparation of heterobifunctional nitroxides: ?,ß-unsaturated ketones, ß-ketoesters, cyano-nitro-derivatives. Canadian Journal of Chemistry, 60: 1432–1438.

1. Hideg K., Hankovszky H. O., Lex L., Kulcsár Gy. (1980) Nitroxyls; VI. Synthesis and Reactions of 3-Hydroxymethyl-2,2,5,5-tetramethyl-2,5-dihydropyrrole-1-oxyl and 3-Formyl Derivatives. Synthesis-Stuttgart, 911–914.

Published in Journals, quotable abstracts

14. Czömpöly T., Kulcsár Gy., Gaál D., Mézes B., Langmár Z., Bors M., Zsákai Cs., Géczy M. (2013) Preclinical and clinical exploration of the perspective to use small substances of the circulatory system in the treatment of cancer. International Journal of Molecular Medicine, 32 (Suppl. 1): S-44.

13. Kulcsár Gy., Czömpöly T., Gaál D., Mézes B. (2013) Experimental results supporting the role of certain small substances of the circulatory system in the defense against tumors and offering an interesting perspective in the treatment of cancer. International Journal of Molecular Medicine, 32 (Suppl. 1): S-44.

12. Kulcsár Gy., Czömpöly T. (2010) The experimental results supporting the existence of the Passive Antitumor Defense System. Magyar epidemiológia – Hungarian Epidemiology, 4: S-37-38.

11. Varjas T., Gombos K., Nowrasteh G., Kulcsár Gy., Ember I. (2006) Investigation on the effect of CuleSol solution in animal experience. Magyar epidemiológia – Hungarian Epidemiology, 3: S-84.

10. Olasz L., Nyarady Z., Tornoczky T., Kinczel G., Progner M., Kulcsar Gy. (2005) Results of induction BVM chemotherapy + Culevit in treatment of head and neck cancer. Magyar epidemiológia – Hungarian Epidemiology, 2: S-69.

9. Kulcsár Gy. (2005) The role of Culevit products containing the agents of the Passive Antitumor Defense System in cancer prevention and therapy. Magyar epidemiológia – Hungarian Epidemiology, 2: S-51.

8. Olasz L., Kulcsár Gy., Nyárády Z., Tornóczky T., Németh Á., Kinczel G., Prantner I. (2004) Results of neoadjuvant BVM chemotherapy + Culevit tablets for treatment of oro-pharyngeal cancer. Journal of Cranio-Maxillofacial Surgery, 32: 229-230.

7. Olasz L., Kulcsar Gy., Tornoczky T., Nyarady Z., Kinczel G. (2004) Improved results of neoadjuvant BVM chemotherapy using Culevit tablets as an adjuvant. Cancer Detection and Prevention, S-178.

6. Kulcsár Gy. (2004) The influence of a mixture of substances occurring in the circulatory system on the effect of different cytostatic drugs on various tumor and normal cell lines. Cancer Detection and Prevention, S-177-178.

5. Kulcsár Gy., Brunner-Bayer Zs., Gyöngyi Z. (2001) Effect of a mixture of natural substances on carcinogen treated mice. Anticancer Research, 21: 1597.

4. Kulcsár Gy. (2001) The passive antitumor defense system formed by the synergistic action of certain substances (including antioxidants) of the circulatory system and the practical employment of the substances in cancer prevention and therapy. Anticancer Research, 21: 1570.

3. Kulcsár Gy. (2000) An improvement of the efficiency of different cytostatic drugs against various tumor cell lines and reduction of their toxic effect on normal cells by a mixture of substances occurring in the circulatory system. Cancer Detection and Prevention, 24(Suppl. 1): S-215.

2. Kulcsár Gy. (1998) The role of certain substances of the circulatory system in the defense against tumors. Cancer Detection and Prevention, 22(Suppl. 1): S-214.

1. Kulcsár Gy. (1996) Passive antitumor defense system: A new approach. Cell Biology International, 20: 228.

Patents

18. Kulcsár Gy. (2008.06.17.) Pharmaceutical compositions for prevention and treatment of cancerous disease and process for their preparation. Canadian patent, Patent number: 2151826

13-17. Kulcsár Gy. (2006.02.02.) Pharmaceutical compositions for prevention and treatment of cancerous disease and process for their preparation. European patent (German, French, Belgian, Italian patent) Patent number: 0679081.

12. Kulcsár Gy. (2003.11.26.) Pharmaceutical compositions for prevention and treatment of cancerous disease and process for their preparation. Chinese patent, Patent number: 130948.

11. Kulcsár Gy. (2003.09.23.) Farmaceutiska kompositioner för förhindrande och behandling av cancerösa sjukdomar samt process för beredning av dessa. Sverige patent, Patentansöknings-nummer: 9502474-1.

10. Kulcsár Gy. (2003.08.14.) Farmaceutische preparaten voor het voorkomen en behandelen van kankerziekten en werkwijze voor de bereiding ervan. Nederlanden Octrooibewijs, Octrooinummer: 195007.

9. Kulcsár Gy. (2002.11.25.) Pharmaceutical compositions for prevention and treatment of cancerous disease and process for their preparation. Korean patent, Patent number: 0363779.

8. Kulcsár Gy. (2001.11.26.) Pharmazeutische Kompositionen zum Vorbeugen und Heilen von Krebserkrankungen und Verfahren zu Ihrer Herstellung. Österreichisches Patent, Patentnummer: 408414.

7. Kulcsár Gy. (2000.05.22.) Farmaceutický prípravek pro prevenci a léčbu rakovinových chorob. Czech patent, Udeluje patent čislo: 286633.

6. Kulcsár Gy. (1999.09.27.) Farmacevtcseszkij szosztav dlja profilaktiki i lecsenyija rakovüh zabolevanyii. Russzkij patent, No: 2138257.

5. Kulcsár Gy. (1999.03.14.) Kompozycja farmaceutyczna do zapobiegania i leczenia chorób rakowych. Polskiej patent, Numer patentowy: 177981.

4. Kulcsár Gy. (1998.06.08.) Tumoros megbetegedések megelőzésére és kezelésére használható gyógyászati kompozíciók és eljárás azok előállítására. Magyar szabadalom, Lajstromszám: 213 677.

3. Kulcsár Gy. (1998.02.16.) Compositiones farmacéuticas para la prevención y el tratamiento de enfermedades cancerosas y procidimiento para su preparación. Espaňola patente, Numero de solicitud: 9550024.

2. Kulcsár Gy. (1997.10.16.) Pharmaceutical compositions for prevention and treatment of cancerous disease and process for their preparation. Australian patent, Patent number: 682.735.

1. Kulcsár Gy. (1996.07.31.) Arzneimittelkompositionen zum Vorbeugen und Heilen von Krebserkrankungen und Verfahren zu Ihrer Herstellung. Erfindungspatent für die Schweiz und Liechtenstein, Patentnummer: 686 867.

Congress presentations

20. Czömpöly T., Kulcsár Gy., Gaál D., Mézes B., Langmár Z., Bors M., Zsákai Cs., Géczy M. Preclinical and clinical exploration of the perspective to use small substances of the circulatory system in the treatment of cancer. 18th World Congress on Advances in Oncology and 16th International Symposium on Molecular Medicine, Crete, Greece, 2013.

19. Kulcsár Gy., Czömpöly T., Gaál D., Mézes B. Experimental results supporting the role of certain small substances of the circulatory system in the defense against tumors and offering an interesting perspective in the treatment of cancer. 18th World Congress on Advances in Oncology and 16th International Symposium on Molecular Medicine, Crete, Greece, 2013. (Invited Speaker)

18. Kulcsár Gy., Czömpöly T. The Natural Antitumor Defense, preclinical investigations and clinical trials. Nordisk Naturmedisinsk Fagkongress, Sundvolden, Norway, 2012. (Invited Speakers)

17. Kulcsár Gy., Gaál D., Kulcsár P. I., Schulcz Á., Czömpöly T. A mixture of amino acids and other small molecules suppresses the growth of murine and human tumors in vivo. Advances in Medical Biotechnology, Pécs, 2010.

16. Kulcsár Gy., Czömpöly T. The experimental results supporting the existence of the Passive Antitumor Defense System. International Conference of Preventive Medicine and Public Health, Pécs, 2010. (Invited Speaker)

15. Kulcsar Gy. The scientific basis of the effect of Culevit products containing the agents of the Passive Antitumor Defense System. (Bazele stiitifice ale efectului produsului Culevit asupra imunitatii antitumorale passive.) Congres Bienal de Cancer Mamar, Baile Felix, Republic of Romania, 2010. (Invited Speaker)

14. Kulcsar Gy., Gaal D., Toth Z., Kulcsar P. I., Osz E., Berente Z. and Halasz H. Experimental Evidence for Killing the Resistant Cells and Raising the Efficacy of Cytostatics by a New Anticancer Drug Candidate (Culevit Infusion) Developed on the Basis of the Passive Antitumor Defence System. EHRLICH II – 2nd World Conference on Magic Bullets: Celebrating the 100th Anniversary of the Nobel Prize Award to Paul Ehrlich, Nürnberg, Germany, 2008. (Invited Speaker)

13. Olasz L., Nyarady Z., Tornoczky T., Kinczel G., Progner M., Kulcsar Gy. Results of induction BVM chemotherapy + Culevit in treatment of head and neck cancer. 2nd Conference of the Society of the Hungarian Molecular and Predictive Epidemiology, Pécs, 2005.

12. Kulcsár Gy. The role of Culevit products containing the agents of the Passive Antitumor Defense System in cancer prevention and therapy. 2nd Conference of the Society of the Hungarian Molecular and Predictive Epidemiology, Pécs, 2005. (Invited speaker)

11. Olasz L., Kulcsar Gy., Tornoczky T., Nyarady Z., Kinczel G., Prantner I. Results of neoadjuvant BVM chemotherapy + Culevit tablets for treatment of oropharyngeal cancer. 5th International Danubius Conference on Oral and Maxillofacial Surgery jointly with the 8th Congress of the Hungarian Association of Oral and Maxillofacial Surgeons, Budapest, 2004.

10. Olasz L., Kulcsar Gy., Tornoczky T., Nyarady Z., Kinczel G. Improved results of neoadjuvant BVM chemotherapy using Culevit tablets as an adjuvant. 7th International Symposium on Predictive Oncology and Intervention Strategies, Nice, France, 2004.

9. Kulcsár Gy. The influence of a mixture of substances occurring in the circulatory system on the effect of different cytostatic drugs on various tumor and normal cell lines. 7th International Symposium on Predictive Oncology and Intervention Strategies, Nice, France, 2004. (Invited Speaker)

8. Kulcsár Gy. The role of the agents of Passive Antitumor Defense System (PADS) in cancer prevention and therapy. 1st Conference of the Hungarian Society for Molecular and Predictive Epidemiology, Pécs, 2003. (Invited Speaker)

7. Kulcsár Gy. Evidence for the passive antitumor defense system formed by the synergistic action of certain small substances of the circulatory system and experiments with the mixture of substances that is a possible new anticancer agent. International IIAR Conference on New Anticancer Agents, Athens, Greece, 2001. (Invited Speaker)

6. Kulcsár Gy. The passive antitumor defense system formed by the synergistic action of certain substances (including antioxidants) of the circulatory system and the practical employment of the substances in cancer prevention and therapy. International IIAR Conference on Antioxidants in Cancer Prevention and Therapy, Athens, Greece, 2001. (Invited Speaker)

5. Kulcsár Gy. Pasivní protinádorový obranný mechanizmus: hypotéza, experimentální důkazy a možnosti praktického využití-Culevit. III. Lékarská Konference, Pardubice, Czech Republic, 1998. (Invited Speaker)

4. Kulcsár Gy. The role of certain substances of the circulatory system in the defense against tumors. 4th International Symposium on Predictive Oncology and Therapy, Nice, France, 1998. (Invited Speaker)

3. Kulcsár Gy. The Passive Antitumor Defence System and the Culevit food supplement developed on the basis of it. III International Conference: Immunity and Nutrition, Beograd, Yugoslavia, 1998. (Invited Speaker)

2. Kulcsár Gy. “Culevit” a food supplement developed on the base of Passive Antitumor Defence System. Conference of the Medical Committee of the Hungarian Fitness League and the Scientific Committee on Sport, Budapest, 1997. (Invited Speaker)

1. Kulcsár Gy. Evidence for the Existence of the Passive Antitumor Defense System. First Eurasia Congress of Medicine, Győr, 1994.

Posters

8. Kulcsár Gy., Gaál D., Tóth Z., Kulcsár P. I., Ősz E., Berente Z., Halász H. Preclinical Experiments on Culevit Infusion Developed on the Basis of a Passive Antitumor Defence System and Investigation of Mechanism. 1st International Conference on Drug Design & Discovery, Dubai, UAE, 2008. (Invited)

7. Varjas T., Gombos K., Nowrasteh G., Kulcsár Gy., Ember I. Investigation on the effect of CuleSol solution in animal experience. Magyar Molekuláris és Prediktív Epidemiológiai Társaság III. Nemzetközi kongresszusa, Pécs, 2006.

6. Olasz L., Kulcsár Gy., Nyárády Z., Tornóczky T., Németh Á., Kinczel G., Prantner I. Results of neoadjuvant BVM chemotherapy + Culevit tablets for treatment of oro-pharyngeal cancer. XVIIth Congress of the European Association for Cranio-Maxillofacial Surgery, Tours, France, 2004.

5. Kulcsár Gy., Gyöngyi Z. The in vivo effects of Culesol infusion on tumor growth. Third European Spring Oncology Conference, Marbella, Malaga, Spain, 2004.

4. Olasz L., Kulcsár Gy., Tornóczky T., Nyárády Z., Kinczel G. Improved results of neoadjuvant BVM chemotherapy using Culevit tablets as an adjuvant. 7th International Symposium on Predictive Oncology and Intervention Strategies, Nice, France, 2004.

3. Kulcsár Gy. The influence of a mixture of substances occurring in the circulatory system on the effect of different cytostatic drugs on various tumor and normal cell lines. 7th International Symposium on Predictive Oncology and Intervention Strategies, Nice, France, 2004. (Invited)

2. Kulcsár Gy., Brunner-Bayer Z., Gyöngyi Z. Effect of mixture of natural substances on carcinogen-treated mice. International IIAR Conference on New Anticancer Agents, Athens, Greece, 2001.

1. Kulcsár Gy. Further experimental evidence for the existence of a passive antitumor defense system formed by the synergistic action of certain small substances of the circulatory system. 5th International Symposium on Predictive Oncology and Therapy, Geneva, Switzerland, 2000. (Invited)

NOTE: There are many other publications in Hungarian language. You can read them here.